Curis Inc CRIS

NAS: CRIS | ISIN: US2312692005   26/04/2024
14,47 USD (-0,34%)
(-0,34%)   26/04/2024

5 april 2024 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 april 2024 · Curis to Present at Upcoming Healthcare Conferences in April · Persbericht

8 februari 2024 · Curis Provides Fourth Quarter 2023 Business Update · Persbericht

1 februari 2024 · Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 · Persbericht

5 januari 2024 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

12 december 2023 · Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study · Persbericht

11 december 2023 · Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference · Persbericht

6 december 2023 · Curis Announces Three Presentations at ASH · Persbericht

5 december 2023 · Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma · Persbericht

2 november 2023 · Curis Provides Third Quarter 2023 Business Update · Persbericht

26 oktober 2023 · Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 · Persbericht

6 oktober 2023 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

12 september 2023 · Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer · Persbericht

6 september 2023 · Curis to Present at Upcoming Healthcare Conferences in September · Persbericht

3 augustus 2023 · Curis Provides Second Quarter 2023 Business Update · Persbericht

28 juli 2023 · Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 · Persbericht

6 juli 2023 · FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID · Persbericht

6 juli 2023 · Curis Announces $15.1 Million Registered Direct Offering · Persbericht

5 mei 2023 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 mei 2023 · Curis Provides First Quarter 2023 Business Update · Persbericht

Mijn selecties